Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations. In addition to our broad portfolio, we have an accomplished team of scientists, novel technology platforms and end-to-end capabilities from new target discovery to GMP manufacturing. We believe that combination therapies and a deep understanding of each patientâs cancer will be key drivers of success in substantially expanding the patient population benefiting from current immuno-oncology therapies. At Agenus, we believe we have assembled the capabilities to bring curative treatments to patients. Source
No articles found.
111,Inc., co-founded by Gang Yu and Junling Liu in 2010, is a leading digital and ...
111,Inc., co-founded by Gang Yu and Junling Liu...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Count.It connects with wearable tracking devices and apps to power community fitne...
Count.It connects with wearable tracking device...
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...
Cellectis is a clinical-stage biopharmaceutical...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
We are a vertically integrated commercial biopharmaceutical company that develops,...
We are a vertically integrated commercial bioph...
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pha...
Established in 2007, and headquartered in Wakef...
Join the National Investor Network and get the latest information with your interests in mind.